EyePoint, Inc. EYPT
Regular-session close
After hours · Nov 20, 7:54 PM ET
- YTD
- -98.72%
- 1 year
- -98.28%
5D -0.0725 (-23.64%)
- Market cap
- 26.65M
- Revenue (ttm)
- 2.79M
- EPS (ttm)
- -3.97
- Shares out
- 83.84M
- Forward P/E
- -4.89
- YTD return
- -98.72%
- 1-year return
- -98.28%
- 50-day average
- 13.11
- 200-day average
- 14.14
- Volume
- 4.94M
- Avg volume
- 8.43M
- Open
- 0.26
- Previous close
- 0.2642
- Day's range
- 0.2277 – 0.265
- 52-week range
- 0.2342 – 18.85
- Beta
- 1.74
- Analysts
- Strong Buy
- Price target
- 40.93 (+17375.9%)
Key statistics
- Enterprise value
- 1.25B
- Price / sales
- 443.56
- Price / book
- 37.25
- Revenue growth
- 161.70%
- Free cash flow
- -155.01M
- Total cash
- 45.26M
- Total debt
- 17.62M
- Return on equity
- -148.70%
- Short % of float
- 21.99%
Fundamental scorecard
5 of 25 checks passed on EYPT’s reported financials
5of 25 checks passed
- Value 2 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.8897 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -1.01 | -1.09 | -0.08 | -7.92% |
| May 6, 2026 | Mar 31, 2026 | -0.79 | -0.99 | -0.20 | -25.32% |
| Mar 4, 2026 | Dec 31, 2025 | -0.78 | -0.81 | -0.03 | -3.85% |
| Nov 5, 2025 | Sep 30, 2025 | -0.77 | -0.85 | -0.08 | -10.39% |
| Aug 6, 2025 | Jun 30, 2025 | -0.67 | -0.85 | -0.18 | -26.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Chardan Capital | main | Buy | Buy |
| Aug 6, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Aug 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 16, 2026 | Stifel | init | — | Buy |
| Jul 1, 2026 | Chardan Capital | main | Buy | Buy |
| Jun 24, 2026 | Guggenheim | reit | Buy | Buy |
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eyepoint.bio
News
Kaplan Fox & Kilsheimer LLP Alerts EyePoint, Inc. (EYPT) Investors to a Securities Class Action Deadline on January 19, 2027
EYPT DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds EyePoint (EYPT) Investors of Securities Class Action Lawsuit Deadline on January 19, 2027
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages EyePoint, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Lawsuit - EYPT
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against EyePoint, Inc. (EYPT) - Investors Who Suffered Losses Are Encouraged to Contact the Firm
12 Health Care Stocks Moving In Thursday's After-Market Session
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages EyePoint, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Lawsuit - EYPT
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against EyePoint, Inc. (NASDAQ: EYPT) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
EYPT Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against EyePoint, Inc.
Faruqi & Faruqi, LLP Urges EyePoint, Inc. (EYPT) Investors to Seek Counsel Before the January 19, 2027 Lead Plaintiff Deadline in the Securities Class Action
EYPT Investors Have Opportunity to Lead EyePoint, Inc. Securities Fraud Lawsuit
Your note
Sign in to keep a note on EYPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDO GORAN A | Director | Purchase | Aug 20, 2024 | 13,150 |
| CORMORANT ASSET MANAGEMENT ,L.P | Unknown | Sale | Dec 3, 2025 | 0 |
| DICICCO WENDY FRANCES | Director | Purchase | Aug 19, 2024 | 9,967 |
| DUKER JAY S | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 9, 2026 | 187,025 |
| ELSTON GEORGE O | Chief Financial Officer | Conversion of Exercise of derivative security | May 21, 2026 | 121,691 |
| LANDIS JOHN B | Director | Conversion of Exercise of derivative security | Jan 2, 2025 | 21,400 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.62% | 8,296,375 | 122.37M | Mar 30, 2026 |
| Cormorant Asset Management, LP | 9.59% | 8,265,000 | 121.91M | Mar 30, 2026 |
| Blackrock Inc. | 8.66% | 7,463,197 | 110.08M | Jun 29, 2026 |
| Federated Hermes, Inc. | 6.59% | 5,681,052 | 83.80M | Jun 29, 2026 |
| Franklin Resources, Inc. | 5.86% | 5,048,598 | 74.47M | Mar 30, 2026 |
| Janus Henderson Group PLC | 4.18% | 3,601,168 | 53.12M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 3.21% | 2,771,487 | 40.88M | Apr 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.02% | 2,600,860 | 38.36M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.36% | 2,033,206 | 29.99M | Jun 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 2.30% | 1,982,000 | 29.23M | Apr 29, 2026 |
| Franklin Strategic Series-FRANKLIN SMALL CAP GROWTH FUND | 1.75% | 1,506,751 | 22.22M | Apr 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.44% | 1,245,583 | 18.37M | Mar 30, 2026 |
